Summary

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

• Paclitaxel (albumin-bound particles), or Abraxane, is used for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer (NSCLC), and metastatic adenocarcinoma of the pancreas. It is often employed after the failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
• Information was derived from 26 systematic reviews and meta-analyses.
• In the treatment of Metastatic Pancreatic Ductal Adenocarcinoma, NALIRIFOX showed superior progression-free survival (PFS) and overall survival compared to a regimen including Abraxane. However, it was associated with a higher incidence of severe diarrhea, while GEM-NABP had lower PFS but fewer side effects.
• For Non-Small Cell Lung Cancer patients who are not candidates for curative surgery or radiation therapy, Nab-Paclitaxel demonstrated improved objective response rate and partial response rate compared to control groups, especially as a second-line treatment after prior chemotherapy.
• Safety outcomes indicated that FOLFIRINOX was associated with hematological toxicities in comparison to GEM-NABP, which included Abraxane; however, evidence on the reduction of adverse events with nab-paclitaxel treatments remains insufficient, indicating gaps in establishing its safety advantages over other treatments.
• When combined with flavonoids, there seems to be a synergistic effect enhancing paclitaxel's mechanisms, making it potentially beneficial in breast cancer treatment according to one study, highlighting an interesting area for future research.
• Platinum-based neoadjuvant therapy, when added to a taxane-anthracycline-containing regimen, could potentially become the standard care for triple-negative breast cancer, indicating that powerful combinations with similar drugs like Abraxane.
• Subgroup considerations and population-specific findings were noted, particularly regarding ovarian implications for different ethnic groups, suggesting the need for tailored approaches based on demographic and individual patient factors to optimize treatment efficacy and minimize toxicity.